ELDN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	146 819
Vidutinė apimtis	95 681.00
Rinkos kapitalizacija	55.41M
EPS	$0 ( 2024-04-04 )
Kita pelno data	( $-0.370 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.400
ATR14	$0.0160 (0.70%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-02	Robinson James A. Jr.	Buy	150 437	Stock Option (Right to Buy)
2023-10-02	Kirk Allan	Buy	150 437	Stock Option (Right to Buy)
2023-10-01	Robinson James A. Jr.	Buy	0
2023-10-02	Kirk Allan	Buy	0
2023-05-05	Bvf Partners L P/il	Buy	3 084 090	Warrants to Purchase Common Stock

INSIDER POWER
100.00
Last 95 transactions
Buy: 17 704 764 \| Sell: 1 858 032

Tūris Koreliacija

Ilgas: 0.10 (neutral)

Trumpas: 0.51 (weak)

Signal:(51.425) Neutral

Eledon Pharmaceuticals, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
GLPG	0.883
HAIN	0.848
NSTG	0.845
ONEM	0.844
RMRM	0.842
CLLS	0.841
FREQ	0.833
SOPA	0.832
MLAB	0.825
AIHS	0.825

10 Labiausiai neigiamai susiję koreliacijos
ACLS	-0.87
RDI	-0.865
INOD	-0.859
DMAC	-0.851
SPSC	-0.849
IESC	-0.846
CTLP	-0.845
NVTS	-0.844
VRRM	-0.84
ALOR	-0.84

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Eledon Pharmaceuticals, Koreliacija - Valiuta/Žaliavos

-0.45
( neutral )

-0.63
( weak negative )

0.00
( neutral )

-0.50
( neutral )

0.47
( neutral )

Eledon Pharmaceuticals, Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-374 000 (0.00 %)
EPS:	$-1.640

FY	2023
Pajamos:	$0
Bruto pelnas:	$-374 000 (0.00 %)
EPS:	$-1.640

FY	2022
Pajamos:	$0
Bruto pelnas:	$-373 000 (0.00 %)
EPS:	$-6.13

FY	2021
Pajamos:	$120 000
Bruto pelnas:	$120 000 (100.00 %)
EPS:	$-17.31

Financial Reports:

No articles found.

Eledon Pharmaceuticals,

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.